Literature DB >> 6292536

Acute polyarthritis associated with active Epstein-Barr virus infection.

C G Ray, E P Gall, L L Minnich, J Roediger, C De Benedetti, J J Corrigan.   

Abstract

Nine patients with an initial onset of symptoms of acute arthritis within the preceding four weeks were enrolled in a prospective serological study with clinical follow-up for six months to two years. Four adults with chronic rheumatoid arthritis and ten healthy adults were similarly studied. Serial titers measured included antibodies to Epstein-Barr virus (EBV) antigens, group B coxsackieviruses, rubella virus, cytomegalovirus, and herpes simplex virus. Serological evidence of active EBV infection was found in four of the patients with acute arthritis, none of the patients with chronic arthritis, and one of the ten healthy adults. There was no similar correlation between acute disease and presence of antibodies to the other viruses tested. We suggest that EBV may cause acute rheumatic illnesses more commonly than is currently appreciated but is probably not involved in the etiology of typical chronic rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292536

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  3 in total

Review 1.  Mechanisms of viral pathogenesis in rheumatic disease.

Authors:  A Perl
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

2.  Localized Outbreaks of Epidemic Polyarthritis among Military Personnel Caused by Different Sublineages of Ross River Virus, Northeastern Australia, 2016-2017.

Authors:  Wenjun Liu; Joanne R Kizu; Luke R Le Grand; Christopher G Moller; Tracy L Carthew; Ian R Mitchell; Ania J Gubala; John G Aaskov
Journal:  Emerg Infect Dis       Date:  2019-10       Impact factor: 6.883

Review 3.  Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Arthritis Res Ther       Date:  2008-09-18       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.